National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Economic evaluation of Agomelatine (Valdoxan®) for the treatment of major depressive disorder.

Pharmacoeconomic Evaluation

Commenced Completed Outcome
April 2009 03/09/09 Reimbursement not recommended.

3rd September 2009 – At the current price agomelatine (Valdoxan®) is not considered cost-effective for the treatment of major depressive episodes under the Community Drugs Schemes.

11th December 2009 – Following a revision in price application we now consider agomelatine (Valdoxan®) cost effective under the Community Drugs schemes.  The product will now be added to the list of items reimbursable under the schemes.


Agomelatine (Valdoxan) summary